Anti-Human RANKL (Denosumab Biosimilar)
Catalog #500019
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500019 | 1 mg | $150.00 | ||
| 500019 | 5 mg | $500.00 | ||
| 500019 | 20 mg | $1,250.00 |
Product Details
Denosumab biosimilar is a fully human IgG2 monoclonal antibody that specifically targets RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key regulator of bone resorption and osteoclast activity. As a biosimilar to the reference biologic Denosumab, this antibody is designed for bone metabolism research, osteoporosis studies, and oncology-related bone disease investigations.
Specifications
| Clone | Denosumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG2 |
| Recommended Isotype Control | Human IgG2 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 5.2 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human RANK Ligand |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |